Pfizer, BioNTech clinical data finds COVID-19 vaccine safe for ages 5-11

Pfizer, BioNTech

Pfizer data finds vaccine safe for children. Positive trial results reported in ages 5-11.

Where: NY and Mainz, Germany

The Facts

On September 20th, Pfizer and BioNTech announced positive results in the Phase 2/3 clinical trial of their COVID-19 vaccine (Comirnaty) in children aged 5 to 11.

A Pfizer-BioNTech press release stated, “In participants 5 to 11 years of age, the vaccine was safe, well-tolerated, and showed robust neutralizing antibody responses.”

In the clinical trial, participants aged 5-11 received a ten microgram dose approximately 21 days apart. (30 micrograms is used for people aged 12 and older.)

Participants’ antibody responses were reported similar to those observed in people aged 16-25, who received 30 micrograms doses of the vaccine in a previous Pfizer-BioNTech study.

According to the press release, the companies intend to submit the clinical data to regulatory bodies worldwide, including the FDA and the European Medicines Agency (EMA).

Primary Sources

Direct, authoritative source material on this story.

Reference Articles

Articles Citable has ingested related to this story.

Media Coverage

Why did we include this story

Most covered story by the media today

of articles referenced this story

Coverage by Media Outlet

Media outlets covering this story along with their positive or negative sentiment toward this story.